TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Vitamins Among Children of HIV-infected Women
Brief Summary: The purpose of this study is to examine the effects of multivitamin (B, C, E) supplementation on reducing the risk of morbidity and mortality outcomes among children born to HIV positive mothers, compared to placebo supplementation.


Options:
A: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group
B: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins - vitamins B complex, C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Multivitamins - vitamins B complex, C and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High Dose Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): High Dose Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamins, Breastmilk HIV Shedding, and Child Health
Brief Summary: The purpose of this study is to analyze stored samples and data collected during the conduct of the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257). The aims are to examine the effect of vitamin supplementation on HIV infected women during pregnancy on a number of parameters in breastmilk.


Options:
A: Arm Label: Multivitamins-Single RDA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins-Single RDA | Arm Label: Multivitamins-Multiples of RDA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins-Multiples of RDA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-Multiples of RDA; Assigned to Arm(s): Multivitamins-Multiples of RDA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-Single RDA; Assigned to Arm(s): Multivitamins-Single RDA
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
D: Arm Label: Vitamin A; Type: N/A; Interventions: Dietary Supplement: Vitamin A alone | Arm Label: No Vitamin A; Type: N/A; Interventions: Dietary Supplement: Multivitamins excluding vitamin A, Dietary Supplement: multivitamins including vitamin A, Other: Placebo | Arm Label: Multivitamins; Type: N/A; Interventions: Dietary Supplement: Vitamin A alone, Dietary Supplement: Multivitamins excluding vitamin A, Dietary Supplement: multivitamins including vitamin A | Arm Label: No Multivitamins; Type: N/A; Interventions: Dietary Supplement: Vitamin A alone, Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A alone; Assigned to Arm(s): Multivitamins, No Multivitamins, Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins excluding vitamin A; Assigned to Arm(s): Multivitamins, No Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: multivitamins including vitamin A; Assigned to Arm(s): Multivitamins, No Vitamin A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): No Multivitamins, No Vitamin A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Novel Pharmacological Strategies in Autism
Brief Summary: This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.


Options:
A: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2 Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3 Aripiprazole + D-cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole, Drug: D-cycloserine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 Aripiprazole, 3 Aripiprazole + D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 3 Aripiprazole + D-cycloserine
B: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1: 12 weeks of study drug then 15 weeks of placebo; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 15 weeks of placebo then 12 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 27 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL | Intervention Type: DRUG; Name: Oral cannabidiol 100mg/mL; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug, Arm 3: 27 weeks of study drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug
D: Arm Label: Extended-release guanfacine; Type: EXPERIMENTAL; Interventions: Drug: extended-release guanfacine | Arm Label: Inactive placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Inactive placebo | Intervention Type: DRUG; Name: extended-release guanfacine; Assigned to Arm(s): Extended-release guanfacine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Novel Pharmacological Strategies in Autism
Brief Summary: This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.


Options:
A: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2 Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3 Aripiprazole + D-cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole, Drug: D-cycloserine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 Aripiprazole, 3 Aripiprazole + D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 3 Aripiprazole + D-cycloserine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Novel Pharmacological Strategies in Autism
Brief Summary: This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.


Options:
A: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
B: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
C: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2 Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3 Aripiprazole + D-cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole, Drug: D-cycloserine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 Aripiprazole, 3 Aripiprazole + D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 3 Aripiprazole + D-cycloserine
D: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
B: Arm Label: sapropterin, 100 mg capsules; Type: EXPERIMENTAL; Interventions: Drug: sapropterin | Arm Label: Placebo, matching active drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sapropterin; Assigned to Arm(s): sapropterin, 100 mg capsules | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, matching active drug
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))
D: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2 Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3 Aripiprazole + D-cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole, Drug: D-cycloserine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 Aripiprazole, 3 Aripiprazole + D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 3 Aripiprazole + D-cycloserine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
D: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Etiology, Prevention, and Treatment of Neonatal Infections in the Community
Brief Summary: The purpose of this study is to determine what are the major types of bacteria that cause newborn infections in the community in rural Bangladesh and whether providing an obstetric and neonatal care package will reduce neonatal deaths by 40%.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: IMNCI | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IMNCI; Assigned to Arm(s): 1
B: Arm Label: Arm1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Community Based | Intervention Type: OTHER; Name: Community Based; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
D: Arm Label: Newhints; Type: EXPERIMENTAL; Interventions: Behavioral: Home visits | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home visits; Assigned to Arm(s): Newhints

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Etiology, Prevention, and Treatment of Neonatal Infections in the Community
Brief Summary: The purpose of this study is to determine what are the major types of bacteria that cause newborn infections in the community in rural Bangladesh and whether providing an obstetric and neonatal care package will reduce neonatal deaths by 40%.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: home visitation | Intervention Type: BEHAVIORAL; Name: home visitation; Assigned to Arm(s): 2
B: Arm Label: Wired mothers intervention; Type: EXPERIMENTAL; Interventions: Device: Wired mothers | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Wired mothers; Assigned to Arm(s): Wired mothers intervention
C: Arm Label: Enhanced CHW intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced CHW intervention | Arm Label: Standard of care; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Enhanced CHW intervention; Assigned to Arm(s): Enhanced CHW intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care
D: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Etiology, Prevention, and Treatment of Neonatal Infections in the Community
Brief Summary: The purpose of this study is to determine what are the major types of bacteria that cause newborn infections in the community in rural Bangladesh and whether providing an obstetric and neonatal care package will reduce neonatal deaths by 40%.


Options:
A: Arm Label: community based screening and treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: community based screening and treatment | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: community based screening and treatment; Assigned to Arm(s): community based screening and treatment
B: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
C: Arm Label: EmONC package; Type: EXPERIMENTAL; Interventions: Behavioral: EmONC package | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: EmONC package; Assigned to Arm(s): EmONC package
D: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A

Answer: B